Covestor Ltd lowered its stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE – Free Report) by 29.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 670 shares of the company’s stock after selling 278 shares during the quarter. Covestor Ltd’s holdings in Invesco Biotechnology & Genome ETF were worth $47,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Cetera Investment Advisers raised its stake in shares of Invesco Biotechnology & Genome ETF by 109.3% in the 1st quarter. Cetera Investment Advisers now owns 27,332 shares of the company’s stock valued at $1,769,000 after purchasing an additional 14,271 shares during the period. CreativeOne Wealth LLC boosted its holdings in shares of Invesco Biotechnology & Genome ETF by 45.2% during the first quarter. CreativeOne Wealth LLC now owns 40,351 shares of the company’s stock worth $2,611,000 after acquiring an additional 12,564 shares during the period. One Capital Management LLC boosted its holdings in shares of Invesco Biotechnology & Genome ETF by 31.9% during the second quarter. One Capital Management LLC now owns 25,402 shares of the company’s stock worth $1,646,000 after acquiring an additional 6,137 shares during the period. Archford Capital Strategies LLC acquired a new stake in shares of Invesco Biotechnology & Genome ETF in the second quarter valued at approximately $357,000. Finally, Cetera Advisors LLC acquired a new stake in shares of Invesco Biotechnology & Genome ETF in the first quarter valued at approximately $328,000.
Invesco Biotechnology & Genome ETF Price Performance
Shares of PBE opened at $66.08 on Friday. The firm has a 50 day simple moving average of $69.57 and a two-hundred day simple moving average of $67.61. The company has a market cap of $266.95 million, a P/E ratio of 17.12 and a beta of 0.88. Invesco Biotechnology & Genome ETF has a one year low of $55.21 and a one year high of $72.84.
Invesco Biotechnology & Genome ETF Profile
PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.
Recommended Stories
- Five stocks we like better than Invesco Biotechnology & Genome ETF
- 3 Best Fintech Stocks for a Portfolio Boost
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- 10 Best Airline Stocks to Buy
- Top-Performing Non-Leveraged ETFs This Year
- Short Selling: How to Short a Stock
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Want to see what other hedge funds are holding PBE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invesco Biotechnology & Genome ETF (NYSEARCA:PBE – Free Report).
Receive News & Ratings for Invesco Biotechnology & Genome ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Biotechnology & Genome ETF and related companies with MarketBeat.com's FREE daily email newsletter.